US Pat. No. 10,653,781

PHARMACEUTICAL FORMULATIONS

AMGEN INC., Thousand Oak...

1. A liquid pharmaceutical formulation comprising in acetate buffer a therapeutic protein at a concentration of at least 70 mg/ml and creatine.
US Pat. No. 10,655,061

PROCESS FOR THE PREPARATION OF BLUE-FLOURESCENCE EMITTING CARBON DOTS (CDTS) FROM SUB-BITUMINOUS TERTIARY HIGH SULFUR INDIAN COALS

1. A process for the preparation of blue-fluorescence emitting carbon dots (CDTs) from a carbon source, wherein the carbon source is sub-bituminous tertiary high sulfur coals, wherein the process comprising the steps of:a) pulverizing the sub-bituminous tertiary high sulfur coals to 72 BS or 70 ASTM mesh size (0.211 mm) particles;
b) mixing the pulverized coal obtained in step (a) with 20-30% of an oxidant under ice cold condition, wherein the oxidant is hydrogen peroxide;
c) sonicating the mixture obtained in step (b) at room temperature for 6 hours to obtain a brown-red solution and cooling it in an ice-water bath followed by slow pouring into a beaker containing 500 ml of crushed ice;
d) neutralizing the mixture obtained in step (c) by adding ammonia solution dropwise until pH 7 is attained;
e) filtering the neutralized mixture obtained in step (d) through 0.22-?m polytetrafluoroethylene membrane;
f) dialyzing the filtrate obtained in step (e) in 1 kDa dialysis bag against ultrapure water for 5 days and collecting the solutions;
g) concentrating the solutions obtained in step (f) using rotary evaporation to obtain the desired carbon dots and storing under ice-cold condition.
US Pat. No. 10,656,085

HIGH SENSITIVITY REAL-TIME BACTERIAL MONITOR

BACTUSENSE TECHNOLOGIES L...

1. A method for detecting target elements in a host analyte, said method comprising:providing a substrate containing an ordered array of pores formed in its surface, at least some of said pores having lateral dimensions enabling said target elements to fit therein;
directing said host analyte over the surface of said substrate, such that at least one of said target elements can enter at least one of said pores;
sequentially illuminating said array by a series of lights having different wavelengths;
capturing a sequence of images during said illuminating;
measuring time-dependent spectral reflectance intensity in a corresponding pixel in each of said sequence of images, wherein said pixel is associated with said at least one pore in said array; and
determining based, at least in part, on said measuring, an effective optical thickness of said at least one.
US Pat. No. 10,653,782

RETROVIRAL PARTICLES EXPRESSING SIRT1 EMBEDDED WITHIN PPCN

Nortwestern University, ...

1. A composition comprising a lentiviral particle comprising (a) a nucleic acid sequence with at least 70% sequence identity with SEQ ID NO: 1 and encoding a Sirt1 polypeptide that exhibits deacetylase activity, and (b) a poly(polyethyleneglycol co-citric acid-co-N isopropylacrylamide) (PPCN) carrier material.
US Pat. No. 10,654,806

MENTHYL NICOTINATE SYNTHESIS PROCESS

MULTICHEM IP LLC, Clearw...

1. A process for preparing highly pure menthyl nicotinate in the absence of hazardous solvents, said process comprising the following stepsStep 1: transesterification reaction of menthol with a C1-C4 alkyl ester of nicotinic acid, in the presence of an alkaline catalyst belonging to the class of C1-C4 alkoxides, linear or branched, at a temperature comprised between 40° C. and 150° C., wherein menthol is in a molar ratio comprised between 1:1 and 20:1 with respect to said C1-C4 alkyl ester of nicotinic acid,
said reaction being conducted under partial vacuum to facilitate the removal of C1-C4 alkyl alcohol which is formed by the reaction, and then separating out a residue of the catalyst via filtration to obtain a mixture of reaction products;
Step 2—Distillation of the mixture of reaction products obtained from step 1, in the presence of activated carbons having a concentration between 0.1 and 5%, with respect to the mass of the mixture of reaction products to be distilled, under conditions of temperature and vacuum to distil firstly said C1-C4 alkyl ester of nicotinic acid that has not reacted in step 1, then the menthol that has not reacted in step 1 and subsequently the pure menthyl nicotinate.
US Pat. No. 10,653,783

SUSTAINED RELEASE OF BIOACTIVE FACTORS FROM ZWITTERIONIC HYDROGELS

1. A method of making a cryogel, comprising the steps of:mixing a zwitterionic monomer of 2-(methylacryloyloxy)ethyl]dimethyl-(3-sulfoproplyl)ammonium hydroxide and a crosslinking agent selected from glycerol dimethyacrylate, N,N?-methylbis(acrylamide), and polyethylene glycol, with one or more initiator compounds in an aqueous solution;
cooling the aqueous solution to at least ?20° C. while the monomers are crosslinked to form the cryogel;
thawing the cryogel to room temperature; and
washing the cryogel to remove unreacted monomers, crosslinking agents, and initiator compounds, wherein the cryogel has an average pore size that is greater than about 50 ?m and less than about 100 ?m.
US Pat. No. 10,653,784

HYDROPHOBIC HIGHLY BRANCHED CARBOHYDRATE POLYMERS

Purdue Research Foundatio...

1. A method of making an aqueous composition of an active pharmaceutical ingredient (API) and a solubilizing agent, comprising the steps of:a) providing a highly branched carbohydrate polymer;
b) activating the highly branched carbohydrate polymer using a basic solution;
c) reacting the activated highly branched carbohydrate polymer with a polyalkylene glycol or alkylene oxide to form a modified highly branched carbohydrate polymer;
d) adding to the modified highly branched carbohydrate polymer with a hydrophobic or amphiphilic group to yield said solubilizing agent; and
e) combining said solubilizing agent with API, wherein the hydrophobic or amphiphilic group of step d) comprises octenyl succinate group.
US Pat. No. 10,654,808

TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

GUANGDONG RAYNOVENT BIOTE...

18. A pharmaceutical composition comprising the compound or enantiomer, diastereoisomer, geometric isomer, solvate or pharmaceutically acceptable salt thereof according to claim 1 and at least one pharmaceutically acceptable carrier, the pharmaceutical composition is tablet, suppository, dispersible tablet, enteric tablet, chewable tablet, orally disintegrating tablet, capsule, sugar coated tablet, granule, dry powder, oral solution, small volume injection, or freeze-dried powder injection, the pharmaceutically acceptable carrier includes one or more substances selected from diluents, solubilizers, disintegrants, suspending agents, lubricants, binders, fillers, flavoring agents, sweetening agents, antioxidants, surfactants, preservatives, encapsulants and pigments.
US Pat. No. 10,653,785

COLLAGEN MATERIAL AND METHOD FOR PRODUCING COLLAGEN MATERIAL

Atree, Inc., Tokyo (JP)

1. A method of producing a collagen material, wherein the method comprises:a step for preparing string collagen gels formed and orientated by extruding collagen solution through a nozzle into a container containing a phosphate buffered saline (PBS) solution, and providing a flow of a fixed direction to a collagen solution, wherein a shape of each of the string collagen gels is a string and a direction of an orientation of each of the string collagen gels is a direction of the string shape,
a step for obtaining multiple string collagen gels wherein an orientation of the multiple string collagen gels is controlled,
a step for arranging the multiple string collagen gels in a desired shape,
a step for drying the multiple string collagen gels arranged in the desired shape to couple the multiple string collagen gels to each other, and
a step for introducing a bubble into the string collagen gels by means of at least one of a pressure-reduced pressure method, a gas-liquid shearing method, and a method of introducing a bubble using a membrane having a pore.
US Pat. No. 10,653,787

WATER-BASED CANNABINOID AND OPIOID COMPOSITIONS

IZUN PHARMACEUTICALS CORP...

1. A tablet or capsule consisting essentially of a cannabis extract consisting essentially of at least one phyto-cannabinoid bound to a protein, wherein the protein is selected from the group consisting of: albumin, ? globulin, ? globulin, and ? globulin.
US Pat. No. 10,655,323

CONTACT LAYER WITH A SOLID FILLER COMPONENT

SIKA TECHNOLOGY AG, Baar...

1. A contact layer comprising a solid filler component F and a thermoplastic polymer component P, wherein the amount of the solid filler component F is 10.0-90.0 wt.-% based on the total weight of the contact layer, and the solid filler component F comprises at least one mineral binder selected from hydraulic binders,wherein the contact layer comprises not more than 2.5 wt.-% of hydrated mineral binders, based on the total weight of the contact layer,
wherein the thermoplastic polymer component P comprises at least one polymer selected from the group consisting of ethylene-vinyl acetate co-polymers (EVA), ethylene-acrylic ester copolymers, ethylene-?-olefin co-polymers, ethylene-propylene co-polymers, polypropylene (PP), polyethylene (PE), polyvinylchloride (PVC), polyethylene terephthalate (PET), polystyrene (PS), polyamides (PA), chlorosulfonated polyethylene (CSPE), ethylene propylene diene rubber (EPDM), and polyisobutylene (PIB), and mixtures thereof, and
wherein a surface of the contact layer has a 3D-average roughness (Sa) according to EN ISO 25178 of at least 10.0 ?m.
US Pat. No. 10,658,653

ELECTRODE MIXTURE PASTE FOR SODIUM SECONDARY CELL, POSITIVE ELECTRODE FOR SODIUM SECONDARY CELL, AND SODIUM SECONDARY CELL

SUMITOMO CHEMICAL COMPANY...

1. A method for producing an electrode mixture paste for a sodium secondary battery comprising: a step of kneading a positive electrode active material that is doped and undoped with a sodium ion, an electroconductive material, a binder, an organic solvent, and an acid having a valence number of 2 or more selected from the group consisting of an organic acid, phosphoric acid, boric acid, and sulfuric acid,wherein the amount of addition of the acid having a valence number of 2 or more is 0.25 wt % or more and 5 wt % or less.
US Pat. No. 10,653,789

POLYMER-DRUG CONJUGATES FOR COMBINATION ANTICANCER THERAPY

The Regents of the Univer...

1. A pharmaceutical composition, comprising:a first therapeutically active agent, wherein the first therapeutically active agent is doxorubicin;
a second therapeutically active agent, wherein the second therapeutically active agent is camptothecin; and
a biocompatible polymer, wherein the biocompatible polymer is hyaluronic acid;
wherein the molar ratio of camptothecin and doxorubicin is greater than 2;
wherein the combination index of a molar ratio of the first and second therapeutically active agents is less than one; and
wherein the first and second therapeutically active agents are conjugated to the biocompatible polymer directly via covalent bonds or indirectly via linkers.
US Pat. No. 10,655,069

PROCESS FOR THE SYNTHESIS OF HYDROCARBONS FROM SYNTHESIS GAS IN THE PRESENCE OF A CATALYST BASED ON COBALT TRAPPED IN A MESOPOROUS OXIDE MATRIX AND OBTAINED FROM AT LEAST ONE MONOMERIC PRECURSOR

IFP Energies Nouvelles, ...

1. A process comprising synthesizing linear paraffinic hydrocarbons from a feed comprising carbon monoxide and hydrogen in the presence of a catalyst comprising a mesoporous oxide matrix and a content by weight of element cobalt in the range of 0.5% to 60%, expressed as the % by weight of metal with respect to the total weight of said catalyst, said process comprising subjecting said feed to synthesis conditions in the presence of the catalyst,wherein the catalyst has:
a specific surface area of 90 to 400 m2/g,
a pore volume of 0.2 to 0.6 mL/g, and
a pore diameter of 5 to 9 nm, and
said catalyst has been prepared by a process comprising:a) mixing, in an aqueous or hydro-organic solvent, at least one molecular precursor comprising cobalt, at least one surfactant and at least one molecular precursor of said mesoporous oxide matrix comprising at least one element X that is silicon, aluminium, titanium, zirconium, cerium or a mixture thereof, said molecular precursor comprising cobalt being dissolved in said aqueous or hydro-organic solvent;b) spray drying the mixture obtained in a) to result in the formation of spherical liquid droplets;c) drying said spherical droplets to obtain solid particles at a temperature in the range of 10° C. to 300° C.;c1) heat treating the solid particles obtained from c), which heat treating is carried out upstream of d) at a temperature in the range of 130° C. to 1000° C., for a period of less than 72 h, andd) activating said solid particles by a reduction treatment forming nanoparticles of cobalt with an oxidation state of 0.
US Pat. No. 10,658,656

HIGH VOLTAGE POSITIVE ACTIVE MATERIAL AND METHOD FOR PREPARING THE SAME

LG Chem, Ltd., (KR)

1. A cathode active material comprising:particles of a spinel-type compound having a composition represented by Formula (2);
wherein the particles of the spinel-type compound has a material present on surfaces of the particles of the spinel-type compound, wherein the material consists of particles consisting of a carbon-based material:
Li1+aNibMcMn2?(b+c)O4?zAz  (2)
where M is at least one selected from the group consisting of Ti, Co, Al, Cu, Fe, Mg, B, Cr, Zr, Zn and period II transition metals,
A is a monoanion or dianion, and
?0.1?a?0.1, 0.3?b?0.6, 0?c?0.2, and 0?z?0.1,
wherein the carbon-based material is physically and/or chemically bonded to the surfaces of the particles of the spinel-type compound of Formula (2),
wherein an average particle diameter (D50) of the carbon-based material is equal to or greater than 2 nm and equal to or less than 500 nm, and
the cathode active material is prepared by mixing the spinel-type compound of Formula (2) and a carbon precursor to form a resulting mixture, wherein the carbon precursor and the spinel-type compound are mixed using dry mixing, wherein the carbon precursor is petroleum-based pitch; and
thermally treating the resulting mixture at a temperature of 400 to 800° C. under an inert atmosphere or an oxygen deficient atmosphere with an oxygen concentration of 35% by volume or less.
US Pat. No. 10,653,791

ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS

BRISTOL-MYERS SQUIBB COMP...

1. A method of preparing an antibody comprising a modified heavy chain constant region, comprising the steps of:(a) providing an antibody comprising a hinge and/or a CH1 domain that is not an IgG2 hinge and/or IgG2 CH1 domain;
(b) replacing the hinge and/or the CH1 domain with an IgG2 hinge and/or IgG2 CH1 domain, respectively, wherein the modified heavy chain constant region comprises a CH1 domain, a hinge, a CH2 domain, and a CH3 domain in order from N- to C-terminus, wherein:
(i) the hinge comprises the amino acid sequence of SEQ ID NO: 129, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 130, or SEQ ID NO: 127;
(ii) the CH1 domain comprises the amino acid sequence of SEQ ID NO: 7;
(iii) the CH2 domain comprises the amino acid sequence of SEQ ID NO: 4 or the amino acid sequence of SEQ ID NO: 24; and
(iv) the CH3 domain comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 5 with the amino acid substitutions E356D and M358L according to the EU index as in Kabat;
or wherein the modified heavy chain constant region comprising the CH1 domain, the hinge, the CH2 domain, and the CH3 domain as defined in (i), (ii), (iii) and (iv) lacks the C-terminal GK or K.
US Pat. No. 10,653,792

ANTI-LY6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE

Genentech, Inc., South S...

1. A method of treating an individual having a Ly6E-positive cancer, the method comprising administering to the individual an effective amount of an immunoconjugate comprising an isolated, monoclonal, humanized antibody that binds to Ly6E and a cytotoxic agent, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:10; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:11; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:12; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:7; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:8; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:9.
US Pat. No. 10,654,048

RECOVERY OF MOLYBDENUM USING SODIUM METABISULFITE AND A THIOCARBONATE DEPRESSANT

Chevron Phillips Chemical...

1. A flotation process for the recovery of molybdenum from a copper-molybdenum concentrate, the process comprising:contacting a molybdenum collector composition comprising sodium metabisulfite and a thiocarbonate compound; with
the copper-molybdenum concentrate, the copper-molybdenum concentrate comprising water, copper, and molybdenum to form a flotation composition; and
subjecting the flotation composition to flotation to recover the molybdenum.
US Pat. No. 10,654,816

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

NOVARTIS INFLAMMASOME RES...


and pharmaceutically acceptable salts thereof.
US Pat. No. 10,653,793

ANTIBODY-DRUG CONJUGATES AND USES THEREOF

Immunomedics, Inc., Morr...

1. A method of treating metastatic breast cancer comprising administering to a human patient with a Trop-2 positive metastatic breast cancer an immunoconjugate sacituzumab govitecan (IMMU-132) wherein the immunoconjugate is administered at a dosage of between 8 mg/kg and 10 mg/kg.
US Pat. No. 10,658,659

ELECTROACTIVE MATERIALS FOR METAL-ION BATTERIES

Nexeon Limited, Abingdon...

1. A particulate material comprising a plurality of composite particles, wherein the composite particles comprise:(a) a porous carbon framework comprising micropores and mesopores, wherein
(i) the micropores and mesopores have a total pore volume as measured by gas adsorption of P1 cm3/g, wherein P1 has a value of at least 0.6 and no more than 1.6,
(ii) the volume fraction of micropores (?a) is in the range from 0.5 to 0.9, based on the total volume of micropores and mesopores;
(iii) the volume fraction of pores having a pore diameter no more than 10 nm (?10) is at least 0.75, based on the total volume of micropores and mesopores, and
(iv) the porous carbon framework has a D50 particle size of less than 20 ?m;
(b) a plurality of nanoscale elemental silicon domains located within the micropores and/or mesopores of the porous carbon framework;wherein the weight ratio of silicon to the porous carbon framework in the composite particles is in the range from [1×P1 to 1.9×P1]:1.